The National Institute of Mental Health’s $9-million bet on aggressive autism drug development reflects the dearth of treatment options for the disorder. Will this ‘fast-fail’ approach pay off?
Spectrum: Autism Research News
Conversations with researchers at the 2013 International Meeting for Autism Research in San Sebastián, Spain, raised provocative questions about the nature of autism. How do we make sense of its staggering heterogeneity, multiple genetic causes and widespread overlap with other disorders?
Watch the complete replay of Flora Vaccarino describing how to model brain development using induced pluripotent stem cells. Submit your own follow-up questions.
A candidate drug for Angelman syndrome shows promise in activating the gene silenced in people with the disorder, and only that gene. Why doesn’t it unsilence other genes?